drugset
drugset / Trial / NCT06370351

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations

NCT06370351 ↗

Phase 1/2 Active not recruiting 12 enrolled Sensorion
Non-randomizedSequentialOpen-labelTreatment

Summary

This study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.

Timeline

Start
2024-06-21
Primary completion
2027-07
Completion
2031-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SENS-501 Unknown — Other

Indications

autosomal recessive nonsyndromic hearing loss 9 disorder of ear prelingual non-syndromic genetic hearing loss sensorineural hearing loss disorder